New hope for tough lymphoma: experimental drug MT-2111 targets relapsed DLBCL
NCT ID NCT05658562
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tests a new drug called MT-2111 for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least two prior treatments. The first part of the study finds a safe dose, and the second part checks if the drug shrinks tumors. About 46 Japanese adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aso Iizuka Hospital
Iizuka-shi, Fukuoka, 820-8505, Japan
-
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, 135-0063, Japan
-
Disaster Medical Center
Tachikawa-shi, Tokyo, 190-0014, Japan
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Gifu Municipal Hospital
Gifu, Gifu, 500-8513, Japan
-
Gunma Prefectural Cancer Center
Ota-shi, Gunma, 373-8550, Japan
-
Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, 466-8650, Japan
-
Japanese Red Cross Nagasaki Genbaku Hospital
Nagasaki, Nagasaki, 852-8104, Japan
-
Japanese Red Cross Society Himeji Hospital
Himeji-shi, Hyōgo, 670-8540, Japan
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
Kyushu Cancer Center
Fukuoka, Fukuoka, 811-1395, Japan
-
Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai
Osaka, Osaka, 530-0025, Japan
-
Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
Osaka Saiseikai Nakatsu Hospital
Osaka, Osaka, 530-0012, Japan
-
Shimane University Hospital
Izumo-shi, Shimane, 693-8501, Japan
-
Shinshu University Hospital
Matsumoto-shi, Nagano, 390-8621, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, 113-8677, Japan
-
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566, Japan
-
Yamagata University Hospital
Yamagata, Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.